Why PSMA imaging is unique from other prostate cancer imaging technologies
We've never had an imaging agent like this before,” says Leonard S. Marks, MD.
In this video, Leonard S. Marks, MD, gives an overview of the Journal of Urology review on prostate-specific antigen membrane imaging for prostate cancer. He details how this technology will affect the detection and treatment of patients with this disease and is hopeful of its real-world application in the future. Marks is a deKernion Endowed Chair in Urology at the David Geffen School of Medicine at the University of California, Los Angeles.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
![Study compares 18F-based PSMA radiotracers to [68Ga]Ga-PSMA-11](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Furologytimes%2F05175eccc72521b2df7a5a848d1602a44b55382e-640x640.webp%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "Study compares 18F-based PSMA radiotracers to [68Ga]Ga-PSMA-11")
Bone scans overstage prostate cancer vs PSMA-PET in initial setting
November 21st 2023"Rather than receiving definitive radiation treatment for localized disease, these patients may have received treatment aimed at preventing the further spread of what was incorrectly identified as metastatic disease," says Thomas Hope, MD.
